Clinical Observation Of Sanqi Shengwei Pill Combined With Quadruple Therapy In The Treatment Of Chronic Atrophic Gastritis Caused By Hp Infection

Objective To observe the clinical efficacy and safety of Sanqi Shengwei Pill combined with quadruple therapy in the treatment of chronic atrophic gastritis caused by Helicobacter pylori infection,further demonstrate the effectiveness of this prescription in the treatment of chronic atrophic gastritis caused by yin deficiency and blood stasis,and provide basis for clinical application.Methods 80 patients who met the inclusion criteria were divided into two groups by random number table method,40 patients in the treatment group and 40 patients in the control group.The control group was treated with bismuth quadruple therapy and vitacoenzyme tablets,while the treatment group was treated with Sanqi Shengwei Pill on the basis of bismuth quadruple therapy.Both groups were treated with bismuth quadruple therapy for 14 consecutive days,and both Sanqi Shengwei Pill and vitacoenzyme tablets were treated for 4 weeks as a course of treatment.Both groups were treated for 3 courses of treatment.Observe and record the TCM syndrome score,pathological tissue score,pepsinogen,gastrin 17,curative effect of gastroscopy after treatment,Hp eradication rate and adverse drug reactions of the two groups of patients before and after treatment,and compare various indicators,sort out the collected data and data,and use SPSS26.0 for data analysis,and make efficacy evaluation.Results 1.The general situation of the two groups of patients was analyzed,and the results showed that there was no statistically significant difference between the groups in gender,age and course of disease(P>0.05).2.For Hp eradication,the Hp eradication rate in the control group was 82.5%,and the Hp eradication rate in the treatment group was 92.3%,the difference was not statistically significant(P>0.05).3.Compared with the treatment group,the treatment group was better than the control group in improving the symptoms of stomachache,fullness,hunger,dry mouth and dry stool(P<0.05),and the improvement of noisy symptoms was not significant in the two groups(P>0.05).The total effective rate of TCM syndrome was 89.7% in the treatment group and 55.0% in the control group,the difference was statistically significant(P<0.05).4.After treatment,the total effective rate of the two groups was 82.1% in the treatment group and 57.5% in the control group,with a statistically significant difference(P<0.05).In terms of histopathology,the atrophy of gastric mucosa in the two groups improved after treatment,with the effective rate of 79.49% in the treatment group and 55.0% in the control group(P<0.05);There was no significant difference between the two groups in the improvement of intestinal metaplasia(P>0.05).5.In terms of improving the secretion function of gastric mucosa in the two groups,the levels of PGI,PGR and G-17 in the two groups increased to different degrees after treatment,and the increased level in the treatment group was better than that in the control group(P<0.05);There was no statistically significant difference in the level of PGⅡbetween the two groups before and after treatment(P>0.05).6.In terms of drug safety,the three major routine,liver and kidney function,electrolyte and other related indicators of the patients were examined before and after treatment,and no abnormality was found.The incidence of adverse drug reactions during treatment was 5.1% in the treatment group and12.5% in the control group.The treatment group was lower than the control group,and the difference was not statistically significant(P>0.05).Conclusion For the patients with chronic atrophic gastritis associated with Helicobacter pylori infection,who were diagnosed as yin deficiency and blood stasis type by TCM,on the basis of bismuth four-drug combination therapy to eliminate Hp,the treatment of Sanqi Shengwei Pill can effectively improve the clinical symptoms of the patients,and the effect is rapid.It has good therapeutic effects on the atrophy of gastric mucosa,the improvement of gastric mucosa under gastroscope,the regulation of pepsinogen and G-17 secretion,Its clinical effect is better than the basic treatment of western medicine alone,and it can appropriately delay or even improve the progress of patients.Sanqi Shengwei Pill has good safety at the recommended dosage,without obvious adverse reactions and toxic side effects.It can be used as one of the clinical auxiliary treatment options for patients with chronic atrophic gastritis of yin deficiency and blood stasis type.